Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

18.14 +0.56 (+3.19%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
Via Chartmill
News headline image
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
This biotech focused on precision medicines for cancer and immune disorders disclosed a notable insider sale after a strong year for shares. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
Via MarketBeat
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
Via Stocktwits
Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
Via Stocktwits
Topics Government Stocks
Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗
Via Stocktwits
News headline image
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
Via Stocktwits
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q3 2025 Earnings Beat Estimates, Stock Rises ↗
Monte Rosa Therapeutics (GLUE) Q3 2025 earnings crushed estimates, with revenue of $12.8M. The stock is up on strong results and a cash runway extending into 2028. 
Via Chartmill
Topics Earnings
News headline image
Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Here are the top movers in Monday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗
Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments. 
Via Benzinga
News headline image
Monday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Monday's pre-market session: top gainers and losers ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected ↗
Monte Rosa Therapeutics (GLUE) reported Q2 2025 earnings with revenue beating estimates at $23.2M and a narrower EPS loss of -$0.15. Shares dipped pre-market despite strong results, as investors await... 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders ↗
Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments. 
Via Benzinga
News headline image
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.